Cancer Breakthrough: Scientists Discover Key to Unlocking Immunity Against Breast Cancer

Scientists at the University of Sussex and Zhejiang Chinese Medical University have made a groundbreaking discovery that could revolutionize cancer immunotherapy. The researchers have found that blocking a protein called LMTK3 can prevent breast cancer tumours from turning immune cells into "friends" that help the tumour grow. This breakthrough could lead to the development of new drugs that target LMTK3, potentially delaying or preventing cancer spread and prolonging lives.

Key Takeaways:

• The study reveals that high levels of LMTK3 in breast cancer cells can trick the body's defences and promote tumour growth by turning immune cells into "friends" that help the tumour.
• Blocking LMTK3 with the molecule C28 can prevent this process, allowing immune cells to remain in attack mode and fight the tumour.
• LMTK3 is present in various parts of the body, including the lungs, thyroid, stomach, colon, ovaries, and skin, suggesting that the findings could have positive implications on a range of cancers.
• The study highlights the potential of LMTK3 as a biomarker to help doctors identify patients who are most likely to benefit from treatments targeting this protein.
• The Giamas Lab is working with pharmaceutical partners to develop C28 into a medicine suitable for human trials and to create stronger, more specific follow-up compounds.
• Researchers are also testing the safety of combining LMTK3 drugs with widely used "checkpoint" antibodies to release other immune brakes.
• The team aims to begin measuring LMTK3 levels in routine biopsy samples to match future drugs to patients' individual needs.

Statistics:

• 50% of breast cancer patients have high levels of LMTK3 in their tumours, which is associated with poorer survival rates. (Source: University of Sussex)
• The study involved extensive treatments with the molecule C28, which was found to block LMTK3 and prevent tumour growth. (Source: Molecular Cancer)
• Researchers performed pre-clinical studies to test the safety of combining LMTK3 drugs with checkpoint antibodies. (Source: Giamas Lab)
• The Giamas Lab is working with hospital teams to measure LMTK3 levels in routine biopsy samples. (Source: University of Sussex)

Sources:

• "Breakthrough study reveals how cancer cells trick immune cells to promote tumour growth" - University of Sussex
• "Molecular Cancer" - Molecular Cancer
• Giamas Lab - University of Sussex
• Zhejiang Chinese Medical University - Zhejiang Chinese Medical University